{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T08:38:26Z","timestamp":1792485506239,"version":"4.5.0"},"reference-count":0,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"am","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tenosynovial giant cell tumor (TGCT) is a locally aggressive neoplasm caused by colony-stimulating factor 1 (CSF1) gene dysregulation. Vimseltinib is an oral, switch-control tyrosine kinase inhibitor of the CSF1 receptor. In part 1 of the MOTION phase 3 trial, vimseltinib demonstrated statistically significant and clinically meaningful improvements in antitumor activity and clinical outcome assessments (COAs). Here, we report long-term results from MOTION in patients with &amp;gt;2 years of follow-up on study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>MOTION is a randomized, double-blind, placebo-controlled, phase 3 trial with double-blind (part 1; to week 25), open-label (part 2; weeks 25\u201349), and extension periods (NCT05059262). Eligible adult patients with histologically confirmed TGCT not amenable to surgery received vimseltinib 30\u2009mg twice weekly. Efficacy was assessed by objective response rate (ORR) on study evaluated by independent radiological review per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) and Tumor Volume Score. COAs and safety were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 118 patients received vimseltinib during MOTION (randomized to vimseltinib, n\u2009=\u200983; crossover, n\u2009=\u200935), with 51% (60\/118) remaining on treatment. ORR on study per RECIST v1.1 was 48% (40\/83) for patients randomized to vimseltinib and 54% (19\/35) for crossover. Patients in both groups experienced long-term improvements in COAs. The safety profile was consistent with prior reports, with no evidence of cholestatic hepatotoxicity or drug-induced liver injury.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Vimseltinib continued to provide robust and durable antitumor activity and demonstrated long-term improvements in COAs, with manageable safety for the treatment of patients with TGCT not amenable to surgery.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag421","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:39:40Z","timestamp":1792481980000},"source":"Crossref","is-referenced-by-count":0,"title":["Long-term efficacy, clinical outcomes, and safety of vimseltinib in patients with tenosynovial giant cell tumor: results from the MOTION phase 3 trial"],"prefix":"10.1093","author":[{"given":"Vivek","family":"Bhadri","sequence":"first","affiliation":[{"name":"Chris O\u2019Brien Lifehouse , Camperdown,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Gelderblom","sequence":"additional","affiliation":[{"name":"Leiden University Medical Center , Leiden, the","place":["Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Stacchiotti","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Istituto Nazionale dei Tumori , Milano,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Bauer","sequence":"additional","affiliation":[{"name":"University Hospital Essen, University Duisburg-Essen, Essen, Germany, and German Cancer Consortium (DKTK), Partner Site University Hospital Essen Department of Medical Oncology and Sarcoma Center\/West German Cancer Center, , Essen,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J","family":"Wagner","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute , Boston, MA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiel","family":"van de Sande","sequence":"additional","affiliation":[{"name":"Leiden University Medical Center , Leiden, the","place":["Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas M","family":"Bernthal","sequence":"additional","affiliation":[{"name":"University of California Los Angeles , Los Angeles, CA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"L\u00f3pez Pousa","sequence":"additional","affiliation":[{"name":"Hospital de la Santa Creu i Sant Pau , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albiruni","family":"Abdul Razak","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Center , Toronto, Ontario,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Italiano","sequence":"additional","affiliation":[{"name":"Institut Bergoni\u00e9 and University of Bordeaux , Bordeaux,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahbubl","family":"Ahmed","sequence":"additional","affiliation":[{"name":"University College London Hospitals NHS Foundation Trust , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Le Cesne","sequence":"additional","affiliation":[{"name":"Gustave Roussy , Villejuif,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Tinoco","sequence":"additional","affiliation":[{"name":"The Ohio State University Division of Medical Oncology, , Columbus, OH,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjetil","family":"Boye","sequence":"additional","affiliation":[{"name":"Oslo University Hospital , Oslo,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Mart\u00edn-Broto","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital, University Hospital General de Villalba, Instituto de Investigacti\u00f3n Sanitaria Fundaci\u00f3n Jim\u00e9nez D\u00edaz (IIS, FJD, UAM) , Madrid,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Palmerini","sequence":"additional","affiliation":[{"name":"IRCCS Istituto Ortopedico Rizzoli , Bologna,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Tafuto","sequence":"additional","affiliation":[{"name":"Istituto Nazionale Tumori IRCCS Fondazione \u201cG.Pascale,\u201d Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Pratap","sequence":"additional","affiliation":[{"name":"Oxford University Hospitals NHS Foundation Trust Oxford Cancer and Haematology Centre, Churchill Hospital, , Oxford,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin C","family":"Powers","sequence":"additional","affiliation":[{"name":"University of Kansas Cancer Center Medical Oncology Division, , Overland Park, KS,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Reichardt","sequence":"additional","affiliation":[{"name":"HELIOS Klinikum Berlin-Buch , Berlin,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Casado Herr\u00e1ez","sequence":"additional","affiliation":[{"name":"Hospital Universitario San Carlos , Madrid,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Rutkowski","sequence":"additional","affiliation":[{"name":"Maria Sklodowska-Curie National Research Institute of Oncology , Warszawa,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Tait","sequence":"additional","affiliation":[{"name":"Deciphera Pharmaceuticals, LLC , Waltham, MA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Agnello","sequence":"additional","affiliation":[{"name":"Deciphera Pharmaceuticals, LLC , Waltham, MA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke","family":"Harrow","sequence":"additional","affiliation":[{"name":"Deciphera Pharmaceuticals, LLC , Waltham, MA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Saunders","sequence":"additional","affiliation":[{"name":"Deciphera Pharmaceuticals, LLC , Waltham, MA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maitreyi G","family":"Sharma","sequence":"additional","affiliation":[{"name":"Deciphera Pharmaceuticals, LLC , Waltham, MA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew L","family":"Sherman","sequence":"additional","affiliation":[{"name":"Deciphera Pharmaceuticals, LLC , Waltham, MA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Blay","sequence":"additional","affiliation":[{"name":"Centre L\u00e9on B\u00e9rard , Lyon,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D","family":"Tap","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College , New York, NY,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,19]]},"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag421\/72124979\/oyag421.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag421\/72124979\/oyag421.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:39:41Z","timestamp":1792481981000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article\/doi\/10.1093\/oncolo\/oyag421\/8943956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,19]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag421","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,19]]},"article-number":"oyag421"}}